Join our project

ALA Diagnostics has launched a funding round to complete the development of the first test for the early diagnosis of Multiple Sclerosis in blood.

This product will revolutionise the diagnosis of MS by allowing an early, simple, fast, cheap and reliable diagnosis in a non-invasive way, as it only requires a blood test to carry it out.

Our diagnostic kit is based on a patented recombinant protein that has been clinically validated in 598 human samples through clinical studies with patients.

We have the only clinically validated biomarker for the diagnosis of MS in blood. There is no other on the market. It is a test that can be easily integrated into the clinical routine and is supported by clinicians, patient organisations and healthcare systems.

Our diagnostic kit reduces costs and the time needed to detect the disease and helps eliminate misdiagnosis, which facilitates diagnosis and allows treatments to be initiated at the earliest stages of the disease, improving its efficacy and therefore the quality of life of patients.

It is a universal test that, because of its simplicity and low cost, can be used to diagnose MS in any country in the world and help MS sufferers anywhere in the world, without the need for complex equipment or large investments.